Replimune Group, Inc. $REPL Shares Purchased by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its position in Replimune Group, acquiring 80,640 additional shares, bringing its total holdings to 950,399 shares worth approximately $9.27 million.
• Multiple institutional investors, including Dimensional Fund Advisors and Tower Research Capital, significantly increased their stakes in Replimune Group during the fourth quarter, highlighting growing interest in the company.
• Replimune Group's stock received several downgrades from analysts, with JPMorgan and Leerink Partners lowering their ratings and target prices, reflecting a more cautious outlook for the company.

Parkman Healthcare Partners LLC boosted its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 9.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 950,399 shares of the company's stock after buying an additional 80,640 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 1.23% of Replimune Group worth $9,266,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Graham Capital Management L.P. lifted its stake in Replimune Group by 6.1% in the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock valued at $365,000 after buying an additional 1,731 shares in the last quarter. Deutsche Bank AG lifted its stake in Replimune Group by 0.4% in the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock valued at $5,496,000 after buying an additional 2,140 shares in the last quarter. Arizona State Retirement System lifted its stake in Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock valued at $151,000 after buying an additional 2,545 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Replimune Group by 7.8% in the 1st quarter. MetLife Investment Management LLC now owns 40,598 shares of the company's stock valued at $396,000 after buying an additional 2,939 shares in the last quarter. Finally, Algert Global LLC lifted its stake in Replimune Group by 7.1% in the 4th quarter. Algert Global LLC now owns 45,820 shares of the company's stock valued at $555,000 after buying an additional 3,057 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Trading Down 3.6%

Shares of Replimune Group stock traded down $0.22 during mid-day trading on Tuesday, hitting $5.82. The stock had a trading volume of 1,413,418 shares, compared to its average volume of 2,553,040. The firm has a 50-day moving average of $6.89 and a two-hundred day moving average of $8.60. Replimune Group, Inc. has a 12-month low of $2.68 and a 12-month high of $17.00. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The firm has a market cap of $454.29 million, a P/E ratio of -1.80 and a beta of 0.51.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 9,154 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer owned 134,368 shares of the company's stock, valued at $721,556.16. This represents a 6.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 5.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on REPL shares. Piper Sandler downgraded shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a report on Tuesday, July 22nd. Barclays downgraded shares of Replimune Group from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $17.00 to $3.00 in a report on Wednesday, July 23rd. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $9.00 price objective (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Wedbush reiterated a "neutral" rating and issued a $4.00 price objective (down previously from $19.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Finally, HC Wainwright reiterated a "neutral" rating on shares of Replimune Group in a report on Monday. Two research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $6.50.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.